<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-055752</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Intravitreal injection of Bevacizumab for pseudophakic cystoid macular edema resistant to steroids</dc:title>
<dc:description xml:lang="en">Clinical case: A 71-year-old man presented with pseudophakic cystoid macular edema (PCME) and    a visual acuity (VA) of 0.1. He had been treated    with 2 intra-vitreal injections of triamcinolone acetonide    (4 mg) 16 months previously. One week after    the intra-vitreal injection of bevacizumab (1.25    mg), VA improved to 0.33, and the OCT demonstrated    decreased macular thickness. Two months    after the injection, no ocular complications were  observed, VA was 0.5 and the OCT showed a significant reduction in the retinal thickness. Conclusion: Intra-vitreal injection of bevacizumab  may be an additional tool for the treatment of therapy-resistant PCME (AU)</dc:description>
<dc:creator>Amselem, L</dc:creator>
<dc:creator>Torralba, C</dc:creator>
<dc:creator>Montero, J</dc:creator>
<dc:creator>Díaz-Llopis, M</dc:creator>
<dc:creator>Cervera, E</dc:creator>
<dc:creator>García-Delpech, S</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Paciente varón de 71 años con edema  macular quístico pseudofáquico (EMQP) y agudeza    visual (AV) de 20/200 que fue previamente tratado    con 2 inyecciones intravítreas de acetónido de    triamcinolona (4 mg) 16 meses atrás. Una semana    tras inyección intravítrea de bevacizumab (1,25    mg), la AV mejoró a 20/60, y la OCT demostró    reducción del espesor retiniano. Dos meses tras la    inyección los autores no observaron ninguna complicación    ocular, una AV de 20/40 y la OCT reveló    un importante adelgazamiento retiniano.    Conclusión: La inyección intravítrea de bevacizumab    puede aportar una nueva opción para los    pacientes con EMQP resistente a tratamiento (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;82(7): 447-450, jul. 2007. ilus</dc:source>
<dc:identifier>ibc-055752</dc:identifier>
<dc:title xml:lang="es">Inyección intravítrea de bevacizumab para edema macular quístico pseudofáquico resistente a esteroides</dc:title>
<dc:subject>^d7442</dc:subject>
<dc:subject>^d920^s22000</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d22708^s22000</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d28131^s22057</dc:subject>
<dc:subject>^d906^s22000</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d4419</dc:subject>
<dc:type>article</dc:type>
<dc:date>200707</dc:date>
</metadata>
</record>
</ibecs-document>
